PTEN, the Achilles' heel of myocardial ischaemia/reperfusion injury?
- PMID: 17293884
- PMCID: PMC2013879
- DOI: 10.1038/sj.bjp.0707155
PTEN, the Achilles' heel of myocardial ischaemia/reperfusion injury?
Abstract
Myocardial ischaemia/reperfusion injury leading to myocardial infarction is one of the most frequent causes of debilitation and death in man. Considerable research has been undertaken to investigate the possibility of reducing myocardial infarction and increasing cell survival by activating certain endogenous prosurvival signaling pathways. Thus, it has been established that the activation of the PI3K (Phosphoinositide-3 kinase)/Akt (Protein kinase B, PKB) signaling pathway is essential for protection against ischaemia/reperfusion injury. This pathway has been shown to be activated by mechanical procedures (e.g. pre and post conditioning) as well as by a number of pharmacological agents. Although the activation of this prosurvival signaling pathway induces the phosphorylation of a large number of substrates implicated in increased cell survival, when activated over a prolonged period this pathway can have detrimental consequences by facilitating unwanted growth and malignancies. Importantly PTEN (phosphatase and tensin homolog deleted on chromosome ten), is the main phosphatase which negatively regulates the PI3K/Akt pathway. In this review we discuss: a) the significance and the limitations of inhibiting PTEN in myocardial ischaemia/reperfusion injury; b) PTEN and its relationship to ischaemic preconditioning, c) the role of PTEN in the development of tolerance to chronic administration of drugs known to limit infarction by activating PI3K/Akt pathway when given acutely, and d) the possible role of PTEN in the ischaemic/reperfused diabetic heart. The experimental evidence discussed in this review illustrates the importance of PTEN inhibition in the protection of the heart against ischaemia/reperfusion injury.
Figures


Similar articles
-
Selective inhibition of PTEN preserves ischaemic post-conditioning cardioprotection in STZ-induced Type 1 diabetic rats: role of the PI3K/Akt and JAK2/STAT3 pathways.Clin Sci (Lond). 2016 Mar;130(5):377-92. doi: 10.1042/CS20150496. Epub 2015 Dec 14. Clin Sci (Lond). 2016. PMID: 26666444
-
Kinases and phosphatases in ischaemic preconditioning: a re-evaluation.Basic Res Cardiol. 2010 Jul;105(4):495-511. doi: 10.1007/s00395-010-0086-3. Epub 2010 Feb 2. Basic Res Cardiol. 2010. PMID: 20127248
-
Ischemia-reperfusion injury and cardioprotection: investigating PTEN, the phosphatase that negatively regulates PI3K, using a congenital model of PTEN haploinsufficiency.Basic Res Cardiol. 2008 Nov;103(6):560-8. doi: 10.1007/s00395-008-0735-y. Epub 2008 Jul 5. Basic Res Cardiol. 2008. PMID: 18604624
-
New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway.Cardiovasc Res. 2004 Feb 15;61(3):448-60. doi: 10.1016/j.cardiores.2003.09.024. Cardiovasc Res. 2004. PMID: 14962476 Review.
-
The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning.Trends Cardiovasc Med. 2005 Feb;15(2):69-75. doi: 10.1016/j.tcm.2005.03.001. Trends Cardiovasc Med. 2005. PMID: 15885573 Review.
Cited by
-
Role of Oxidative Stress in Reperfusion following Myocardial Ischemia and Its Treatments.Oxid Med Cell Longev. 2021 May 18;2021:6614009. doi: 10.1155/2021/6614009. eCollection 2021. Oxid Med Cell Longev. 2021. PMID: 34055195 Free PMC article. Review.
-
LncRNA NORAD promotes the progression of myocardial infarction by targeting the miR-22-3p/PTEN axis.Acta Biochim Biophys Sin (Shanghai). 2022 Apr 25;54(4):463-473. doi: 10.3724/abbs.2022037. Acta Biochim Biophys Sin (Shanghai). 2022. PMID: 35607965 Free PMC article.
-
c-Jun N-terminal kinase (JNK-1) confers protection against brief but not extended ischemia during acute myocardial infarction.J Biol Chem. 2011 Apr 22;286(16):13995-4006. doi: 10.1074/jbc.M110.211334. Epub 2011 Feb 15. J Biol Chem. 2011. PMID: 21324895 Free PMC article.
-
Overexpression of the PTEN Gene in Myocardial Tissues of Coronary Bypass Surgery Patients.Arq Bras Cardiol. 2023 Apr 7;120(4):e20220169. doi: 10.36660/abc.20220169. eCollection 2023. Arq Bras Cardiol. 2023. PMID: 37042855 Free PMC article. English, Portuguese.
-
Amelioration of myocardial ischemia/reperfusion injury in diabetes: A narrative review of the mechanisms and clinical applications of dexmedetomidine.Front Pharmacol. 2022 Aug 31;13:949754. doi: 10.3389/fphar.2022.949754. eCollection 2022. Front Pharmacol. 2022. PMID: 36120296 Free PMC article. Review.
References
-
- Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol. 2003a;41:508–515. - PubMed
-
- Bell RM, Yellon DM. Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol. 2003b;35:185–193. - PubMed
-
- Bose AK, Mocanu MM, Carr RD, Yellon DM. Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther. 2005;19:9–11. - PubMed
-
- Brar BK, Stephanou A, Knight R, Latchman DS. Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. J Mol Cell Cardiol. 2002;34:483–492. - PubMed
-
- Bullard AJ, Govewalla P, Yellon DM. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol. 2005;100:397–403. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous